Heterogeneity in Primary Colorectal Cancer and its Corresponding Metastases: A Potential Reason of EGFR-Targeted Therapy Failure?

被引：0
|
作者：
Li, Zhongqi [1 ]
Jin, Ketao [1 ,2 ]
Lan, Huanrong [3 ]
Teng, Lisong [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Surg Oncol, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
[2] Wenzhou Med Coll, Affiliated Zhuji Hosp, Dept Surg, Zhuji, Zhejiang, Peoples R China
[3] Wenzhou Med Coll, Affiliated Zhuji Hosp, Dept Gynecol & Obstet, Zhuji, Zhejiang, Peoples R China
来源：
HEPATO-GASTROENTEROLOGY | 2011年 / 58卷 / 106期
关键词：
Colorectal cancer; Epidermal growth factor receptor; Heterogeneity; Targeted therapy; GROWTH-FACTOR-RECEPTOR; CETUXIMAB PLUS IRINOTECAN; PROGRESSION-FREE-SURVIVAL; K-RAS MUTATIONS; KRAS MUTATIONS; P53; MUTATIONS; INTRATUMOR HETEROGENEITY; PIK3CA MUTATIONS; PRIMARY TUMORS; HUMAN BREAST;
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Epidermal growth factor receptor (EGFR)targeted therapy represents an important approach in metastatic colorectal cancer (CRC) therapy. However, a number of CRC patients show intrinsic or acquired resistance to EGFR-targeted therapy. EGFR antibody therapy is established in CRC patients with wild-type KRAS. However, up to half of these patients do not respond to this therapy. This phenomenon implied some potential mechanisms of resistance to EGFR inhibitors might exist. One of the potential reasons to explain this phenomenon is heterogeneity of CRC. The heterogeneity of CRC has been well described at the morphological, molecular and genomic levels. This review discussed the potential relationship of heterogeneity, including intratumor heterogeneity of CRC and heterogeneity in primary CRC and its corresponding metastases, to EGFR-targeted therapy failure.
引用
收藏
页码：411 / 416
页数：6
相关论文
共 50 条
  • [1] Acquired resistance to EGFR-targeted therapies in colorectal cancer
    Van Emburgh, Beth O.
    Sartore-Bianchi, Andrea
    Di Nicolantonio, Federica
    Siena, Salvatore
    Bardelli, Alberto
    MOLECULAR ONCOLOGY, 2014, 8 (06) : 1084 - 1094
  • [2] EGFR-Targeted therapies in colorectal cancer
    Overman, Michael J.
    Hoff, Paulo M.
    DISEASES OF THE COLON & RECTUM, 2007, 50 (08) : 1259 - 1270
  • [3] KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
    Valtorta, Emanuele
    Misale, Sandra
    Sartore-Bianchi, Andrea
    Nagtegaal, Iris D.
    Paraf, Francois
    Lauricella, Calogero
    Dimartino, Valentina
    Hobor, Sebastijan
    Jacobs, Bart
    Ercolani, Cristiana
    Lamba, Simona
    Scala, Elisa
    Veronese, Silvio
    Laurent-Puig, Pierre
    Siena, Salvatore
    Tejpar, Sabine
    Mottolese, Marcella
    Punt, Cornelis J. A.
    Gambacorta, Marcello
    Bardelli, Alberto
    Di Nicolantonio, Federica
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (05) : 1259 - 1265
  • [4] Tumor Heterogeneity in Primary Colorectal Cancer and Corresponding Metastases. Does the Apple Fall Far From the Tree?
    Blank, Annika
    Roberts, Daniel Edward Il
    Dawson, Heather
    Zlobec, Inti
    Lugli, Alessandro
    FRONTIERS IN MEDICINE, 2018, 5
  • [5] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Leto, Simonetta M.
    Trusolino, Livio
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 709 - 722
  • [6] EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy
    Wei, Q.
    Shui, Y.
    Zheng, S.
    Wester, K.
    Nordgren, H.
    Nygren, P.
    Glimelius, B.
    Carlsson, J.
    ONCOLOGY REPORTS, 2011, 25 (01) : 3 - 11
  • [7] Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer
    Spano, Jean Philippe
    Milano, Gerard
    Vignot, Stephane
    Khayat, David
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 66 (01) : 21 - 30
  • [8] Analysis of the Concordance in the EGFR Pathway Status Between Primary Tumors and Related Metastases of Colorectal Cancer Patients: Implications for Cancer Therapy
    Cejas, P.
    Lopez-Gomez, M.
    Aguayo, C.
    Madero, R.
    Moreno-Rubio, J.
    de Castro Carpeno, J.
    Belda-Iniesta, C.
    Barriuso, J.
    Moreno Garcia, V.
    Diaz, E.
    Burgos, E.
    Gonzalez-Baron, M.
    Feliu, J.
    CURRENT CANCER DRUG TARGETS, 2012, 12 (02) : 124 - 131
  • [9] ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
    Geissler, Anna-Lena
    Geissler, Miriam
    Kottmann, Daniel
    Lutz, Lisa
    Fichter, Christiane D.
    Fritsch, Ralph
    Weddeling, Britta
    Makowiec, Frank
    Werner, Martin
    Lassmann, Silke
    ONCOTARGET, 2017, 8 (10) : 17164 - 17190
  • [10] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Simonetta M. Leto
    Livio Trusolino
    Journal of Molecular Medicine, 2014, 92 : 709 - 722
12345